Literature DB >> 18627046

Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome.

William H Hoffman1, Alka Jain, Harold Chen, Neal S Fedarko.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18627046      PMCID： PMC2562707          DOI： 10.1002/ajmg.a.32395

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN： 1552-4825            Impact factor:   2.802


× No keyword cloud information.
  28 in total

Review 1.  Phakomatosis pigmentokeratotica associated with hypophosphataemic vitamin D-resistant rickets: improvement in phosphate homeostasis after partial laser ablation.

Authors:  A Saraswat; S Dogra; A Bansali; B Kumar
Journal:  Br J Dermatol       Date:  2003-05       Impact factor: 9.302

Review 2.  Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook.

Authors:  B Eriksson; K Oberg
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

3.  Tumor-induced osteomalacia--unveiling a new hormone.

Authors:  M J Econs; M K Drezner
Journal:  N Engl J Med       Date:  1994-06-09       Impact factor: 91.245

4.  Hypophosphatemic rickets/osteomalacia in linear sebaceous nevus syndrome: a variant of tumor-induced osteomalacia.

Authors:  D E Carey; M K Drezner; J A Hamdan; M Mange; M S Ahmad; S Mubarak; W L Nyhan
Journal:  J Pediatr       Date:  1986-12       Impact factor: 4.406

5.  Hypothesis: Jadassohn nevus phakomatosis: a paracrinopathy with variable phenotype.

Authors:  B G Kousseff
Journal:  Am J Med Genet       Date:  1992-07-01

6.  Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density.

Authors:  A Jain; N S Fedarko; M T Collins; R Gelman; M A Ankrom; M Tayback; L W Fisher
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

7.  Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Authors:  Aline Martin; Valentin David; Jennifer S Laurence; Patricia M Schwarz; Eileen M Lafer; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

Review 8.  The wrickkened pathways of FGF23, MEPE and PHEX.

Authors:  Peter S N Rowe
Journal:  Crit Rev Oral Biol Med       Date:  2004-09-01

9.  Epidermal nevus syndromes: clinical findings in 35 patients.

Authors:  Helena Vidaurri-de la Cruz; Lourdes Tamayo-Sánchez; Carola Durán-McKinster; María de la Luz Orozco-Covarrubias; Ramón Ruiz-Maldonado
Journal:  Pediatr Dermatol       Date:  2004 Jul-Aug       Impact factor: 1.588

10.  MEPE has the properties of an osteoblastic phosphatonin and minhibin.

Authors:  P S N Rowe; Y Kumagai; G Gutierrez; I R Garrett; R Blacher; D Rosen; J Cundy; S Navvab; D Chen; M K Drezner; L D Quarles; G R Mundy
Journal:  Bone       Date:  2004-02       Impact factor: 4.398
View more
  8 in total

Review 1.  Disorders of phosphate homeostasis and tissue mineralisation.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Endocr Dev       Date:  2009-06-03

Review 2.  FGF23 and syndromes of abnormal renal phosphate handling.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 3.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

Review 4.  Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.

Authors:  Peter S N Rowe
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2012       Impact factor: 1.807

5.  Treating osteoporosis: a near miss in an unusual case of FGF-23 mediated bone loss.

Authors:  Jinson Paul; Kripa Elizabeth Cherian; Nitin Kapoor; Thomas Vizhalil Paul
Journal:  BMJ Case Rep       Date:  2019-03-16

6.  Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator.

Authors:  Valentin David; Aline Martin; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2009-06-11       Impact factor: 4.736

Review 7.  The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.

Authors:  Peter S N Rowe
Journal:  Cell Biochem Funct       Date:  2012-05-09       Impact factor: 3.685

Review 8.  Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.

Authors:  Michaël R Laurent; Jean De Schepper; Dominique Trouet; Nathalie Godefroid; Emese Boros; Claudine Heinrichs; Bert Bravenboer; Brigitte Velkeniers; Johan Lammens; Pol Harvengt; Etienne Cavalier; Jean-François Kaux; Jacques Lombet; Kathleen De Waele; Charlotte Verroken; Koenraad van Hoeck; Geert R Mortier; Elena Levtchenko; Johan Vande Walle
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-19       Impact factor: 5.555
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.